Non-Hodgkin Lymphoma in Children
Introduction to Non-Hodgkin Lymphoma in Children
Non-Hodgkin Lymphoma (NHL) is a diverse group of malignancies originating from lymphoid tissues, primarily affecting B-cells, T-cells, or natural killer (NK) cells. In children, NHL represents approximately 7% of all childhood cancers, making it the third most common pediatric malignancy after leukemia and brain tumors.
Key Points:
- NHL in children differs significantly from adult NHL in terms of biology, presentation, and prognosis.
- Pediatric NHL is generally more aggressive but also more responsive to treatment than adult NHL.
- The most common subtypes in children are Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma.
- Early diagnosis and prompt treatment are crucial for optimal outcomes.
Epidemiology of Pediatric Non-Hodgkin Lymphoma
Understanding the epidemiology of NHL in children is crucial for early detection and risk assessment.
Key Points:
- Incidence: NHL accounts for about 7% of all childhood cancers in children under 15 years of age.
- Age Distribution: The incidence increases with age, peaking in adolescence.
- Gender: There is a male predominance, with a male-to-female ratio of approximately 2:1 to 3:1.
- Geographic Variation: Burkitt lymphoma is more common in equatorial Africa, associated with Epstein-Barr virus (EBV) infection.
- Risk Factors:
- Primary immunodeficiency disorders (e.g., Wiskott-Aldrich syndrome, ataxia-telangiectasia)
- Acquired immunodeficiency (e.g., HIV infection, post-transplant immunosuppression)
- EBV infection (particularly for Burkitt lymphoma)
- Genetic predisposition (e.g., Li-Fraumeni syndrome)
Pathophysiology of Non-Hodgkin Lymphoma in Children
The pathophysiology of pediatric NHL involves complex genetic and molecular alterations leading to uncontrolled lymphocyte proliferation.
Key Points:
- Cell of Origin: NHL can arise from B-cells, T-cells, or NK cells at various stages of differentiation.
- Genetic Alterations:
- Burkitt lymphoma: t(8;14) translocation involving c-MYC oncogene
- Diffuse large B-cell lymphoma: Various translocations involving BCL6, BCL2, or MYC
- Anaplastic large cell lymphoma: t(2;5) translocation resulting in NPM-ALK fusion protein
- Microenvironment: The tumor microenvironment plays a crucial role in lymphoma growth and survival.
- Immune Dysregulation: Impaired immune surveillance contributes to lymphoma development, especially in immunodeficiency states.
- Viral Oncogenesis: EBV and human herpesvirus 8 (HHV-8) are associated with certain NHL subtypes.
Clinical Presentation of Non-Hodgkin Lymphoma in Children
The clinical presentation of pediatric NHL varies depending on the subtype and site of involvement. Early recognition of symptoms is crucial for timely diagnosis and treatment.
Key Points:
- General Symptoms:
- Painless lymphadenopathy
- B symptoms: fever, night sweats, weight loss
- Fatigue and decreased appetite
- Site-Specific Symptoms:
- Abdominal: pain, distension, intestinal obstruction (common in Burkitt lymphoma)
- Mediastinal: cough, dyspnea, superior vena cava syndrome (common in lymphoblastic lymphoma)
- Head and neck: cervical lymphadenopathy, tonsillar enlargement
- Cutaneous: skin lesions (in anaplastic large cell lymphoma)
- Central nervous system: headache, cranial nerve palsies, spinal cord compression
- Systemic Manifestations:
- Hepatosplenomegaly
- Bone marrow involvement: cytopenia
- Tumor lysis syndrome: metabolic derangements due to rapid cell turnover
Diagnosis of Non-Hodgkin Lymphoma in Children
Accurate diagnosis of pediatric NHL requires a comprehensive approach combining clinical assessment, imaging studies, and pathological evaluation.
Key Points:
- Clinical Evaluation:
- Thorough history and physical examination
- Assessment of B symptoms and performance status
- Imaging Studies:
- Chest X-ray: initial screening for mediastinal masses
- CT scan: evaluation of extent of disease in chest, abdomen, and pelvis
- PET-CT: useful for staging and response assessment
- MRI: preferred for CNS involvement
- Pathological Evaluation:
- Excisional lymph node biopsy (preferred over fine-needle aspiration)
- Immunohistochemistry for lineage determination and subtyping
- Flow cytometry for immunophenotyping
- Cytogenetic and molecular studies (e.g., FISH for specific translocations)
- Additional Investigations:
- Bone marrow aspiration and biopsy
- Cerebrospinal fluid analysis
- Complete blood count, liver and kidney function tests, LDH level
- HIV testing
- Staging:
- St. Jude/Murphy staging system for childhood NHL
- Lugano classification for response assessment
Treatment of Non-Hodgkin Lymphoma in Children
Treatment of pediatric NHL is risk-adapted and varies based on the histological subtype, stage, and patient factors. Multimodal therapy is the cornerstone of management.
Key Points:
- General Principles:
- Treatment is usually intensive and of short duration
- Multiagent chemotherapy is the primary modality
- Radiation therapy has a limited role in most cases
- Supportive care is crucial to manage complications
- Chemotherapy Regimens:
- Burkitt lymphoma and diffuse large B-cell lymphoma:
- FAB/LMB protocols (rituximab, cyclophosphamide, vincristine, doxorubicin, methotrexate, cytarabine)
- BFM protocols
- Lymphoblastic lymphoma: ALL-type protocols (e.g., COG AALL0434)
- Anaplastic large cell lymphoma: ALCL99 or similar protocols (e.g., vinblastine, methotrexate, dexamethasone)
- Burkitt lymphoma and diffuse large B-cell lymphoma:
- CNS Prophylaxis:
- Intrathecal chemotherapy
- High-dose systemic methotrexate
- Targeted Therapies:
- Rituximab for CD20-positive B-cell lymphomas
- Brentuximab vedotin for relapsed/refractory anaplastic large cell lymphoma
- Stem Cell Transplantation:
- Considered for high-risk or relapsed/refractory disease
- Autologous or allogeneic depending on the clinical scenario
- Supportive Care:
- Tumor lysis syndrome prophylaxis and management
- Infection prevention and treatment
- Nutritional support
- Psychosocial support for patients and families
Prognosis of Non-Hodgkin Lymphoma in Children
The prognosis for children with NHL has improved significantly over the past few decades due to advances in treatment strategies. However, outcomes can vary based on several factors.
Key Points:
- Overall Survival:
- 5-year overall survival rates exceed 80% for most pediatric NHL subtypes
- Burkitt lymphoma and diffuse large B-cell lymphoma: 90-95% for localized disease, 80-85% for advanced disease
- Lymphoblastic lymphoma: 80-90%
- Anaplastic large cell lymphoma: 70-80%
- Prognostic Factors:
- Stage at diagnosis (advanced stage associated with poorer prognosis)
- Histological subtype
- Presence of certain genetic alterations (e.g., MYC rearrangements in B-cell lymphomas)
- Response to initial therapy
- Presence of CNS or bone marrow involvement
- Relapse:
- Occurs in approximately 10-20% of patients
- Usually within the first two years after initial treatment
- Prognosis for relapsed disease is generally poorer, but salvage therapy can be successful in some cases
- Long-term Complications:
- Secondary malignancies
- Cardiovascular complications (e.g., from anthracycline exposure)
- Endocrine dysfunction
- Neurocognitive effects
- Fertility issues
- Follow-up:
- Regular monitoring for relapse, especially in the first two years
- Long-term follow-up for late effects of therapy
- Psychosocial support and reintegration into normal life
Non-Hodgkin Lymphoma in Children
- What are the main types of Non-Hodgkin Lymphoma (NHL) in children?
Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), lymphoblastic lymphoma, and anaplastic large cell lymphoma (ALCL) - What is the most common type of NHL in children?
Burkitt lymphoma - What is the typical age of onset for pediatric NHL?
Peak incidence between 7-11 years old - What is the male-to-female ratio in pediatric NHL?
Approximately 3:1, with males more commonly affected - What genetic condition significantly increases the risk of pediatric NHL?
Ataxia-telangiectasia - What virus is associated with Burkitt lymphoma in endemic areas?
Epstein-Barr virus (EBV) - What is the characteristic genetic abnormality in Burkitt lymphoma?
t(8;14) translocation involving the MYC gene - What is the most common presenting symptom of abdominal Burkitt lymphoma?
Abdominal pain and distention - What is the "starry sky" appearance in Burkitt lymphoma?
A histological pattern where macrophages appear as clear spaces against a background of dark blue tumor cells - What staging system is commonly used for pediatric NHL?
St. Jude/Murphy staging system - What is the role of bone marrow biopsy in pediatric NHL staging?
To detect bone marrow involvement, which affects staging and treatment - What imaging modality is considered the gold standard for staging pediatric NHL?
FDG-PET/CT scan - What is the primary treatment modality for pediatric NHL?
Intensive, short-duration combination chemotherapy - What is the role of radiation therapy in pediatric NHL?
Limited, mainly used for emergencies (e.g., superior vena cava syndrome) or CNS disease - What is the significance of CNS prophylaxis in pediatric NHL treatment?
Crucial to prevent CNS relapse, typically involves intrathecal chemotherapy - What is the overall survival rate for pediatric NHL?
Approximately 80-90%, varying by subtype and stage - What is the most common site of extranodal involvement in pediatric NHL?
Abdomen, particularly in Burkitt lymphoma - What is the role of rituximab in pediatric NHL treatment?
Used in combination with chemotherapy for CD20-positive B-cell NHL, improving outcomes - What is the significance of LDH levels in pediatric NHL?
Elevated levels correlate with tumor burden and are a prognostic factor - How does the treatment approach differ for lymphoblastic lymphoma compared to other NHL subtypes?
Treated with acute lymphoblastic leukemia (ALL)-like protocols of longer duration - What is the role of stem cell transplantation in pediatric NHL?
Used for relapsed or refractory disease, particularly in ALCL - What is ALK positivity in ALCL?
Presence of ALK gene rearrangement, associated with better prognosis in ALCL - What is the significance of minimal residual disease (MRD) monitoring in pediatric NHL?
Emerging tool for assessing treatment response and predicting relapse - How does pediatric NHL differ from adult NHL in terms of biology and prognosis?
Pediatric NHL is generally more aggressive but more chemo-sensitive, with better overall prognosis - What is the role of brentuximab vedotin in pediatric NHL treatment?
Used in CD30-positive lymphomas, particularly relapsed or refractory ALCL - What is tumor lysis syndrome in the context of pediatric NHL?
A potentially life-threatening metabolic complication due to rapid tumor cell death, common in Burkitt lymphoma - How does HIV infection impact the risk and presentation of pediatric NHL?
Increases risk, often presents with more advanced disease and extranodal involvement - What is the role of CAR T-cell therapy in pediatric NHL?
Emerging therapy for relapsed/refractory B-cell NHL, showing promising results - What is the significance of double-hit or triple-hit lymphomas in pediatric NHL?
Rare in children, associated with poor prognosis when present - How does the presence of bulky disease affect the treatment approach in pediatric NHL?
May require more intensive chemotherapy and careful monitoring for tumor lysis syndrome
Disclaimer
The notes provided on Pediatime are generated from online resources and AI sources and have been carefully checked for accuracy. However, these notes are not intended to replace standard textbooks. They are designed to serve as a quick review and revision tool for medical students and professionals, and to aid in theory exam preparation. For comprehensive learning, please refer to recommended textbooks and guidelines.
